Bottneuro was selected by the Venture Kick's jury of experts as one of the winners of the second stage of financial and entrepreneurial support. Their projects provide neuromodulation therapies for Alzheimer's disease, offer an efficient all-in-one solution for creating structured medical reports, and develop solutions with far greater flexibility in either stationary or mobile energy storage applications.

Bottneuro: CEO Dr. Bekim Osmani, CTO Alois Hopf, and CSO Dr. Tino Töpper

Bottneuro: neuromodulation therapies for Alzheimer's disease Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease that slowly destroys memory and thinking skills, eventually leading to death from complete brain failure. It is going to be one of the biggest challenges of the 21st century. The current number of people with AD in Europe, the US, and Switzerland exceeds 15 million, with about 11’000 new patients every day. Annual costs are estimated to CHF 440 billion and are expected to rise by 50% until 2030 due to our aging society. Bottneuro offers a unique, non-invasive therapy for early- and moderate-stage AD patients using electrical stimulations of neurons and glia cells in the brain. Positron emission tomography (PET) allows the detection of regions in the brain affected by tau and amyloid depositions. With this information, Bottneuro designs a personalized electrical stimulation therapy. The stimulation device can be used at home while watching TV or reading a newspaper. The team of Bottneuro includes highly experienced managers and experts in different fields of science and medicine. CEO Bekim Osmani graduated from ETH in Biomedical Engineering and Robotics and served in several management positions before completing his Ph.D. in nanoscience at the University of Basel. CTO Alois Hopf graduated from ETH in Biotechnology and is currently a Ph.D. candidate in neuroscience at the University of Basel. Rolf Wildermuth, former country president of Medtronic Switzerland, serves as chairman of the board at Bottneuro. Pascal Brenneisen, with more than 30 years of experience in pharma and life sciences, is board member and will support the business development team to establish a worldwide franchising system. Venture Kick funds will be used for business development and fundraising activities.